Osako Tomofumi | Department Of Breast And Endocrine Surgery Kumamoto City Hospital
スポンサーリンク
概要
関連著者
-
Arima Nobuyuki
Department Of Clinical Pathology Kumamoto City Hospital
-
Nishimura Reiki
Breast And Endocrine Surgery Kumamoto City Hospital
-
Nishimura Reiki
Department Of Breast & Endocrine Surgery Kumamoto City Hospital
-
OSAKO Tomofumi
Department of Breast and Endocrine Surgery, Kumamoto City Hospital
-
Okumura Yasuhiro
Department Of Breast And Endocrine Surgery Kumamoto City Hospital
-
Okumura Yasuhiro
Department Of Breast And Endocrine Surgery Faculty Of Medical And Pharmaceutical Sciences Kumamoto U
-
Hayashi Mitsuhiro
Department Of Breast And Endocrine Surgery Kumamoto City Hospital
-
Osako Tomofumi
Department Of Breast And Endocrine Surgery Kumamoto City Hospital
-
Arima Nobuyuki
Clinical Pathology Kumamoto City Hospital
-
Toyozumi Yasuo
Department Of Pathology Kurume University School Of Medicine
-
TOYOZUMI Yasuo
Department of Clinical Pathology, Kumamoto City Hospital
-
OKUMURA Yasuhiro
Department of Surgery, National Hospital Organization Kumamoto Medical Center
-
Iwase Hirotaka
Breast And Endocrine Surgery Faculty Of Medical And Pharmaceutical Science Kumamoto University
-
Kikuchi Shoichi
Department Of Surgery Japan Self-defense Force Hanshin Hospital
-
HAYASHI Mitsuhiro
Department of Surgical Oncology, Dokkyo Medical University
-
Kikuchi Shoichi
Department Of Surgery Jsdf Kumamoto Hospital
-
Iwase Hirotaka
Department Of Breast And Endocrine Surgery Faculty Of Life Sciences Kumamoto University Graduate School Of Medical Sciences
-
KIKUCHI Shoichi
Department of Mechanical Engineering, Ritsumeikan University
-
KIKUCHI Shoichi
Department of Mechanical Engineering, College of Science and Engineering, Ritsumeikan University
著作論文
- Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis
- Mucocele-like tumor associated with ductal carcinoma in situ diagnosed as mucinous carcinoma by fine-needle aspiration cytology : report of a case
- Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer